14th May 2018 12:04
LONDON (Alliance News) - SkinBioTherapeutics PLC said Monday it had filed a new patent application related to its SkinBiotix probiotic bacteria product.
SkinBioTherapeutics said the patent covers the use of SkinBiotix for increasing filaggrin levels in the skin. Filaggrin is vital for the formation of the outermost protective layer of the skin. Those with severe forms of eczema, SkinBioTherapeutics, explained tend to have half the level of filaggrin when compared to a healthy individual.
"SkinBiotix is continuing to prove its uniqueness as a platform via scientific testing," SkinBioTherapeutics Chief Executive Officer Catherine O'Neill said. "Following the successful work in skin models on fillagrin production, we are looking to increase the value and scope of our intellectual property with the filing of this patent."
"This is a continuation of our strategy to create an IP portfolio that allows us to robustly protect what we believe is a technology of significant commercial value in key global dermatalogical markets", O'Neill added.
Shares in SkinBioTherapeutics were 6.3% higher at 17.00 pence on Monday.
Related Shares:
Skinbiotherap.